Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

tags : Lung cancer    symbols : ABBV    save search

Non-small Cell Lung Cancer Drugs Market to Grow by USD 30.23 billion| Increasing Prevalence and Incidence of Non-small Cell Lung Cancer to Boost Market Growth | Technavio
Published: 2022-03-08 (Crawled : 08:00) - prnewswire.com
AZNCF | News | $140.3 -4.19% 1.5K twitter stocktwits trandingview |
Health Technology
| | O: -2.09% H: 5.03% C: 0.85%
ALPMY | News | $9.49 -1.11% 480K twitter stocktwits trandingview |
Manufacturing
| | O: 1.01% H: 0.81% C: -0.06%
NVS | News | $98.35 1.1% 0.0% 2.2M twitter stocktwits trandingview |
Health Technology
| | O: -4.98% H: 0.0% C: 0.0%
ABBV | News | $167.8 -1.03% -0.06% 4.1M twitter stocktwits trandingview |
Health Technology
| | O: 0.29% H: 0.6% C: -1.24%
SNY | News | $46.66 -2.16% -2.21% 1.7M twitter stocktwits trandingview |
Health Technology
| | O: 3.03% H: 0.0% C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M twitter stocktwits trandingview |
Health Technology
| | O: -0.44% H: 0.0% C: 0.0%
AMGN | News | $273.085 -0.17% -0.17% 2.5M twitter stocktwits trandingview |
Health Technology
| | O: 0.35% H: 0.0% C: 0.0%

drug cel lung cancer cancer drug cancer growth
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M twitter stocktwits trandingview |
Health Technology
| | O: 1.07% H: 0.0% C: 0.0%
CHRS | $2.03 -6.88% -7.39% 720K twitter stocktwits trandingview |
Health Technology
| | O: -0.83% H: 0.0% C: 0.0%

hoice-01 treatment trial lung cancer positive therapy bioscience results cancer phase 3
Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
Published: 2021-09-14 (Crawled : 02:00) - globenewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M twitter stocktwits trandingview |
Health Technology
| | O: 0.47% H: 0.07% C: -1.4%
CHRS | $2.03 -6.88% -7.39% 720K twitter stocktwits trandingview |
Health Technology
| | O: 0.31% H: 0.49% C: -0.86%

treatment lung cancer positive results cancer conference
Positive Interim Results of CHOICE-01 Study Evaluating Junshi Biosciences and Coherus’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
Published: 2021-09-14 (Crawled : 02:00) - globenewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M twitter stocktwits trandingview |
Health Technology
| | O: 0.47% H: 0.07% C: -1.4%
CHRS | $2.03 -6.88% -7.39% 720K twitter stocktwits trandingview |
Health Technology
| | O: 0.31% H: 0.49% C: -0.86%

treatment lung cancer positive results cancer conference
Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-08-19 (Crawled : 02:00) - globenewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M twitter stocktwits trandingview |
Health Technology
| | O: -0.92% H: 2.37% C: 1.48%
CHRS | $2.03 -6.88% -7.39% 720K twitter stocktwits trandingview |
Health Technology
| | O: 1.27% H: 8.73% C: 1.47%

treatment lung cancer positive therapy results cancer phase 3 trial
Coherus and Junshi Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-08-18 (Crawled : 23:00) - globenewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M twitter stocktwits trandingview |
Health Technology
| | O: -0.92% H: 2.37% C: 1.48%
CHRS | $2.03 -6.88% -7.39% 720K twitter stocktwits trandingview |
Health Technology
| | O: 1.27% H: 8.73% C: 1.47%

treatment lung cancer positive therapy results cancer phase 3 trial
Gainers vs Losers
62% 38%

Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M twitter stocktwits trandingview |
Consumer Services

BOF | $1.99 70.09% 41.21% 110M twitter stocktwits trandingview |

ILAG | $0.51 6.03% 40.62% 1.7M twitter stocktwits trandingview |

LICN | $0.941 68.04% 40.49% 15M twitter stocktwits trandingview |

AMST | $3.31 65.5% 39.58% 70M twitter stocktwits trandingview |
Technology Services

MTC | $3.615 61.38% 38.04% 9.3M twitter stocktwits trandingview |
Technology Services

WIMI | $1.15 58.53% 36.92% 19M twitter stocktwits trandingview |
Technology Services

AIH | $0.45 12.5% 30.92% 320K twitter stocktwits trandingview |
Health Services

MULN | News | $3.78 38.46% 27.78% 13M twitter stocktwits trandingview |
Information

RILY | $29.86 37.48% 27.26% 12M twitter stocktwits trandingview |
Finance


Your saved searches
Save your searches and get alerts when important news are released.